Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group
  2. Taxonomy
  3. Term
  4. Other

Incorporating a cognitive function ancillary study in an ophthalmic clinical trial

Go back to Resources

Incorporating a cognitive function ancillary study in an ophthalmic clinical trial

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Initial immunosuppression with Mycophenolate or Tacrolimus is not associated with increased risk for post-transplant lymphoproliferative disorder: a North American Pediatric Cooperative Study (NAPRTCS) Report

Go back to Resources

Initial immunosuppression with Mycophenolate or Tacrolimus is not associated with increased risk for post-transplant lymphoproliferative disorder: a North American Pediatric Cooperative Study (NAPRTCS) Report

Authors:

Location:

Go back to Resources

Investigator-initiated health-related quality-of-life-research

Go back to Resources

Investigator-initiated health-related quality-of-life-research

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Kidney Transplant Study Group: Tacrolimus versus Cyclosporine in Kidney Transplantation: Five year graft survival and renal function

Go back to Resources

Kidney Transplant Study Group: Tacrolimus versus Cyclosporine in Kidney Transplantation: Five year graft survival and renal function

Authors:

Go back to Resources

Kidney Transplant Study Group; Tacrolimus versus Cyclosporine in Kidney Transplantation: Five year graft loss in patients with acute rejection and hypercholesterolemia

Go back to Resources

Kidney Transplant Study Group; Tacrolimus versus Cyclosporine in Kidney Transplantation: Five year graft loss in patients with acute rejection and hypercholesterolemia

Authors:

Go back to Resources

Review of the COBLT Study Processing Procedures

Go back to Resources

Review of the COBLT Study Processing Procedures

Authors:

Location:

Go back to Resources

Risk factors associated with age-related macular degeneration. A case-control study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study Report No. 3

Go back to Resources

Risk factors associated with age-related macular degeneration. A case-control study in the Age-Related Eye Disease Study: Age-Related Eye Disease Study Report No. 3

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

ROP outcome in infants with prethreshold ROP and SpO2 ›94% in room air

Go back to Resources

ROP outcome in infants with prethreshold ROP and SpO2 ›94% in room air

Authors:

Location:

Go back to Resources

Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial 1: Primary outcomes

Go back to Resources

Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized controlled trial 1: Primary outcomes

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

A Freedom of Information Act tale

Go back to Resources

A Freedom of Information Act tale

Authors:

Location:

Go back to Resources

Pagination

  • Previous page ‹‹
  • Page 126
  • Next page ››
Subscribe to Other
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification